A concerted HIF-1α/MT1-MMP signalling axis regulates the expression of the 3BP2 adaptor protein in hypoxic mesenchymal stromal cells

PLoS ONE

Volumn 6, Issue 6, 2011, Pages

  Proulx Bonneau, Sébastien ^a   Guezguez, Amel ^a   Annabi, Borhane ^a  

^a UNIVERSITÉ DU QUÉBEC À MONTRÉAL   (Canada)

Author keywords

[No Author keywords available]

Indexed keywords

ABL SH3 BINDING PROTEIN 2; ADAPTOR PROTEIN; HYPOXIA INDUCIBLE FACTOR 1ALPHA; MATRIX METALLOPROTEINASE 14; UNCLASSIFIED DRUG; VASCULOTROPIN; SH3BP2 PROTEIN, MOUSE; SIGNAL TRANSDUCING ADAPTOR PROTEIN;

AMINO ACID SEQUENCE; ANIMAL CELL; ANIMAL TISSUE; ARTICLE; BINDING SITE; CELL DIFFERENTIATION; CELL MOTILITY; CONTROLLED STUDY; EXTRACELLULAR MATRIX; FEMALE; GENE OVEREXPRESSION; GENE SILENCING; IMMUNOREACTIVITY; MESENCHYME CELL; MOUSE; NONHUMAN; NUCLEOTIDE SEQUENCE; PROMOTER REGION; PROTEIN BINDING; PROTEIN DEGRADATION; PROTEIN EXPRESSION; PROTEIN PHOSPHORYLATION; SIGNAL TRANSDUCTION; STROMA CELL; TRANSCRIPTION REGULATION; UPREGULATION; ANIMAL; C57BL MOUSE; CELL CULTURE; CELL HYPOXIA; CELL MOTION; CELL SURVIVAL; GENE EXPRESSION REGULATION; GENETICS; IMMUNOBLOTTING; MESENCHYMAL STROMA CELL; METABOLISM; PHYSIOLOGY; REVERSE TRANSCRIPTION POLYMERASE CHAIN REACTION; RNA INTERFERENCE;

MURINAE;

ADAPTOR PROTEINS, SIGNAL TRANSDUCING; ANIMALS; CELL HYPOXIA; CELL MOVEMENT; CELL SURVIVAL; CELLS, CULTURED; FEMALE; GENE EXPRESSION REGULATION; GENE SILENCING; HYPOXIA-INDUCIBLE FACTOR 1, ALPHA SUBUNIT; IMMUNOBLOTTING; MATRIX METALLOPROTEINASE 14; MESENCHYMAL STROMAL CELLS; MICE; MICE, INBRED C57BL; REVERSE TRANSCRIPTASE POLYMERASE CHAIN REACTION; RNA INTERFERENCE;

EID: 79959579851     PISSN: None     EISSN: 19326203     Source Type: Journal    
DOI: 10.1371/journal.pone.0021511     Document Type: Article

References (69)

1. Prockop DJ, (1997) Marrow stromal cells as stem cells for nonhematopoietic tissues. Science 276: 71-74.
2. Horwitz EM, Le Blanc K, Dominici M, Mueller I, Slaper-Cortenbach I, et al. (2005) Clarification of the nomenclature for MSC: The International Society for Cellular Therapy position statement. Cytotherapy 7: 393-395.
3. Studeny M, Marini FC, Champlin RE, Zompetta C, Fidler IJ, et al. (2002) Bone marrow-derived mesenchymal stem cells as vehicles for interferon-beta delivery into tumors. Cancer Res 62: 3603-3608.
4. Nakamizo A, Marini F, Amano T, Khan A, Studeny M, et al. (2005) Human bone marrow-derived mesenchymal stem cells in the treatment of gliomas. Cancer Res 65: 3307-3318.
5. Annabi B, Naud E, Lee YT, Eliopoulos N, Galipeau J, (2004) Vascular progenitors derived from murine bone marrow stromal cells are regulated by fibroblast growth factor and are avidly recruited by vascularizing tumors. J Cell Biochem 91: 1146-1158.
6. Birnbaum T, Roider J, Schankin CJ, Padovan CS, Schichor C, et al. (2007) Malignant gliomas actively recruit bone marrow stromal cells by secreting angiogenic cytokines. J Neurooncol 83: 241-247.
7. Yen BL, Yen ML, (2008) Mesenchymal Stem Cells and Cancer- for Better or for Worse? J Cancer Mol 4: 5-9.
8. Dwyer RM, Potter-Beirne SM, Harrington KA, Lowery AJ, Hennessy E, et al. (2007) Monocyte chemotactic protein-1 secreted by primary breast tumors stimulates migration of mesenchymal stem cells. Clin Cancer Res 13: 5020-5027.
9. Djouad F, Plence P, Bony C, Tropel P, Apparailly F, et al. (2003) Immunosuppressive effect of mesenchymal stem cells favors tumor growth in allogeneic animals. Blood 102: 3837-3844.
10. Annabi B, Lee YT, Turcotte S, Naud E, Desrosiers RR, et al. (2003) Hypoxia promotes murine bone-marrow-derived stromal cell migration and tube formation. Stem Cells 21: 337-347.
11. Chi JT, Wang Z, Nuyten DS, Rodriguez EH, Schaner ME, et al. (2006) Gene expression programs in response to hypoxia: cell type specificity and prognostic significance in human cancers. PLoS Med 3: e47.
12. Koh MY, Spivak-Kroizman TR, Powis G, (2010) HIF-1alpha and cancer therapy. Recent Results Cancer Res 180: 15-34.
13. Mylotte LA, Duffy AM, Murphy M, O'Brien T, Samali A, et al. (2008) Metabolic flexibility permits mesenchymal stem cell survival in an ischemic environment. Stem Cells 26: 1325-1336.
14. Ren R, Mayer BJ, Cicchetti P, Baltimore D, (1993) Identification of a ten-amino acid proline-rich SH3 binding site. Science 259: 1157-1161.
15. Deckert M, Tartare-Deckert S, Hernandez J, Rottapel R, Altman A, (1998) Adaptor function for the Syk kinases-interacting protein 3BP2 in IL-2 gene activation. Immunity 9: 595-605.
16. Annabi B, Thibeault S, Lee YT, Bousquet-Gagnon N, Eliopoulos N, et al. (2003) Matrix metalloproteinase regulation of sphingosine-1-phosphate-induced angiogenic properties of bone marrow stromal cells. Exp Hematol 31: 640-649.
17. Karow M, Popp T, Egea V, Ries C, Jochum M, et al. (2009) Wnt signalling in mouse mesenchymal stem cells: impact on proliferation, invasion and MMP expression. J Cell Mol Med 13: 2506-2520.
18. Gingras D, Michaud M, Di Tomasso G, Béliveau E, Nyalendo C, et al. (2008) Sphingosine-1-phosphate induces the association of membrane-type 1 matrix metalloproteinase with p130Cas in endothelial cells. FEBS Lett 582: 399-404.
19. Nyalendo C, Michaud M, Beaulieu E, Roghi C, Murphy G, et al. (2007) Src-dependent phosphorylation of membrane type I matrix metalloproteinase on cytoplasmic tyrosine 573: role in endothelial and tumor cell migration. J Biol Chem 282: 15690-15699.
20. Fortier S, Labelle D, Sina A, Moreau R, Annabi B, (2008) Silencing of the MT1-MMP/G6PT axis suppresses calcium mobilization by sphingosine-1-phosphate in glioblastoma cells. FEBS Lett 582: 799-804.
21. Belkaid A, Fortier S, Cao J, Annabi B, (2007) Necrosis induction in glioblastoma cells reveals a new "bioswitch" function for the MT1-MMP/G6PT signaling axis in proMMP-2 activation versus cell death decision. Neoplasia 9: 332-430.
22. Fortier S, Touaibia M, Lord-Dufour S, Galipeau J, Roy R, et al. (2008) Tetra- and hexavalent mannosides inhibit the pro-apoptotic, antiproliferative and cell surface clustering effects of concanavalin-A: impact on MT1-MMP functions in marrow-derived mesenchymal stromal cells. Glycobiology 18: 195-204.
23. Annabi B, Laflamme C, Sina A, Lachambre MP, Béliveau R, (2009) A MT1-MMP/NF-kappaB signaling axis as a checkpoint controller of COX-2 expression in CD133+ U87 glioblastoma cells. J Neuroinflammation 6: 8.
24. Sina A, Proulx-Bonneau S, Roy A, Poliquin L, Cao J, et al. (2010) The lectin concanavalin-A signals MT1-MMP catalytic independent induction of COX-2 through an IKKgamma/NF-kappaB-dependent pathway. J Cell Commun Signal 4: 31-38.
25. Currie JC, Fortier S, Sina A, Galipeau J, Cao J, et al. (2007) MT1-MMP down-regulates the glucose 6-phosphate transporter expression in marrow stromal cells: a molecular link between pro-MMP-2 activation, chemotaxis, and cell survival. J Biol Chem 282: 8142-8149.
26. Lord-Dufour S, Copland IB, Levros LC Jr, Post M, Das A, et al. (2009) Evidence for transcriptional regulation of the glucose-6-phosphate transporter by HIF-1alpha: Targeting G6PT with mumbaistatin analogs in hypoxic mesenchymal stromal cells. Stem Cells 27: 489-497.
27. Belaiba RS, Bonello S, Zähringer C, Schmidt S, Hess J, et al. (2007) Hypoxia up-regulates hypoxia-inducible factor-1alpha transcription by involving phosphatidylinositol 3-kinase and nuclear factor kappaB in pulmonary artery smooth muscle cells. Mol Biol Cell 18: 4691-4697.
28. Liu L, Yu Q, Lin J, Lai X, Cao W, et al. (2011) HIF-1α is essential for hypoxia-induced mesenchymal stem cell mobilization into the peripheral blood. Stem Cells Dev In press.
29. Strongin AY, (2010) Proteolytic and non-proteolytic roles of membrane type-1 matrix metalloproteinase in malignancy. Biochim Biophys Acta 1803: 133-141.
30. Annabi B, Bouzeghrane M, Moumdjian R, Moghrabi A, Béliveau R, (2005) Probing the infiltrating character of brain tumors: inhibition of RhoA/ROK-mediated CD44 cell surface shedding from glioma cells by the green tea catechin EGCg. J Neurochem 94: 906-916.
31. Annabi B, Thibeault S, Moumdjian R, Béliveau R, (2004) Hyaluronan cell surface binding is induced by type I collagen and regulated by caveolae in glioma cells. J Biol Chem 279: 21888-21896.
32. Tso CL, Shintaku P, Chen J, Liu Q, Liu J, et al. (2006) Primary glioblastomas express mesenchymal stem-like properties. Mol Cancer Res 4: 607-619.
33. Van Meir EG, Hadjipanayis CJ, Norden AD, Shu HK, Wen PY, et al. (2010) Exciting new advances in neuro-oncology: the avenue to a cure for malignant glioma. CA Cancer J Clin 60: 166-193.
34. Schichor C, Birnbaum T, Etminan N, Schnell O, Grau S, et al. (2006) Vascular endothelial growth factor A contributes to glioma-induced migration of human marrow stromal cells (hMSC). Exp Neurol 199: 301-310.
35. Grigoriadis N, Lourbopoulos A, Lagoudaki R, Frischer JM, Polyzoidou E, et al. (2011) Variable behavior and complications of autologous bone marrow mesenchymal stem cells transplanted in experimental autoimmune encephalomyelitis. Exp Neurol In press.
36. Snyder EY, (2011) The risk of putting something where it does not belong: Mesenchymal stem cells produce masses in the brain. Exp Neurol In press.
37. Oliver L, Olivier C, Marhuenda FB, Campone M, Vallette FM, (2009) Hypoxia and the malignant glioma microenvironment: regulation and implications for therapy. Curr Mol Pharmacol 2: 263-284.
38. Belkaid A, Currie JC, Desgagnés J, Annabi B, (2006) The chemopreventive properties of chlorogenic acid reveal a potential new role for the microsomal glucose-6-phosphate translocase in brain tumor progression. Cancer Cell Int 6: 7.
39. Potier E, Ferreira E, Andriamanalijaona R, Pujol JP, Oudina K, et al. (2007) Hypoxia affects mesenchymal stromal cell osteogenic differentiation and angiogenic factor expression. Bone 40: 1078-1087.
40. Rosová I, Dao M, Capoccia B, Link D, Nolta JA, (2008) Hypoxic preconditioning results in increased motility and improved therapeutic potential of human mesenchymal stem cells. Stem Cells 26: 2173-2182.
41. Ramirez-Bergeron DL, Simon MC, (2001) Hypoxia-inducible factor and the development of stem cells of the cardiovascular system. Stem Cells 19: 279-286.
42. Koong AC, Denko NC, Hudson KM, Schindler C, Swiersz L, et al. (2000) Candidate genes for the hypoxic tumor phenotype. Cancer Res 60: 883-887.
43. Yan SF, Lu J, Zou YS, Soh-Won J, Cohen DM, et al. (1999) Hypoxia-associated induction of early growth response-1 gene expression. J Biol Chem 274: 15030-15040.
44. Haas TL, Stitelman D, Davis SJ, Apte SS, Madri JA, (1999) Egr-1 mediates extracellular matrix-driven transcription of membrane type 1 matrix metalloproteinase in endothelium. J Biol Chem 274: 22679-22685.
45. Sperandio S, Fortin J, Sasik R, Robitaille L, Corbeil J, et al. (2009) The transcription factor Egr1 regulates the HIF-1alpha gene during hypoxia. Mol Carcinog 48: 38-44.
46. Deryugin EI, Soroceanu L, Strongin AY, (2002) Up-regulation of vascular endothelial growth factor by membrane-type 1 matrix metalloproteinase stimulates human glioma xenograft growth and angiogenesis. Cancer Res 62: 580-588.
47. Sounni NE, Devy L, Hajitou A, Frankenne F, Munaut C, et al. (2002) MT1-MMP expression promotes tumor growth and angiogenesis through an up-regulation of vascular endothelial growth factor expression. FASEB J 16: 555-564.
48. Chen G, Dimitriou ID, La Rose J, Ilangumaran S, Yeh WC, et al. (2007) The 3BP2 adapter protein is required for optimal B-cell activation and thymus-independent type 2 humoral response. Mol Cell Biol 27: 3109-3122.
49. Shukla U, Hatani T, Nakashima K, Ogi K, Sada K, (2009) Tyrosine phosphorylation of 3BP2 regulates B cell receptor-mediated activation of NFAT. J Biol Chem 284: 33719-33728.
50. Guezguez A, Prod'homme V, Mouska X, Baudot A, Blin-Wakkach C, et al. (2010) 3BP2 Adapter protein is required for receptor activator of NFkappaB ligand (RANKL)-induced osteoclast differentiation of RAW264.7 cells. J Biol Chem 285: 20952-20963.
51. Le Bras S, Moon C, Foucault I, Breittmayer JP, Deckert M, (2007) Abl-SH3 binding protein 2, 3BP2, interacts with CIN85 and HIP-55. FEBS Lett 581: 967-974.
52. Langlois S, Di Tomasso G, Boivin D, Roghi C, Murphy G, et al. (2005) Membrane type 1-matrix metalloproteinase induces endothelial cell morphogenic differentiation by a caspase-dependent mechanism. Exp Cell Res 307: 452-464.
53. Batten P, Rosenthal NA, Yacoub MH, (2007) Immune response to stem cells and strategies to induce tolerance. Philos Trans R Soc Lond B Biol Sci 362: 1343-1356.
54. Krampera M, Glennie S, Dyson J, Scott D, Laylor R, et al. (2003) Bone marrow mesenchymal stem cells inhibit the response of naive and memory antigen-specific T cells to their cognate peptide. Blood 101: 3722-3729.
55. Klyushnenkova E, Mosca JD, Zernetkina V, Majumdar MK, Beggs KJ, et al. (2005) T cell responses to allogeneic human mesenchymal stem cells: immunogenicity, tolerance, and suppression. J Biomed Sci 12: 47-57.
56. Liu G, Atteridge CL, Wang X, Lundgren AD, Wu JD, (2010) The membrane type matrix metalloproteinase MMP14 mediates constitutive shedding of MHC class I chain-related molecule A independent of A disintegrin and metalloproteinases. J Immunol 184: 3346-3350.
57. Kajita M, Itoh Y, Chiba T, Mori H, Okada A, et al. (2001) Membrane-type 1 matrix metalloproteinase cleaves CD44 and promotes cell migration. J Cell Biol 153: 893-904.
58. Joyce N, Annett G, Wirthlin L, Olson S, Bauer G, et al. (2010) Mesenchymal stem cells for the treatment of neurodegenerative disease. Regen Med 5: 933-946.
59. Perasso L, Cogo CE, Giunti D, Gandolfo C, Ruggeri P, et al. (2010) Systemic administration of mesenchymal stem cells increases neuron survival after global cerebral ischemia in vivo (2VO). Neural Plast 2010: 534925.
60. Uccelli A, Benvenuto F, Laroni A, Giunti D, (2011) Neuroprotective features of mesenchymal stem cells. Best Pract Res Clin Haematol 24: 59-64.
61. Kanazawa H, Fujimoto Y, Teratani T, Iwasaki J, Kasahara N, et al. (2011) Bone marrow-derived mesenchymal stem cells ameliorate hepatic ischemia reperfusion injury in a rat model. PLoS One 6: e19195.
62. Zhang Y, Zhang R, Li Y, He G, Zhang D, et al. (2011) Simvastatin augments the efficacy of therapeutic angiogenesis induced by bone marrow-derived mesenchymal stem cells in a murine model of hindlimb ischemia. Mol Biol Rep In press.
63. Eliasson P, Jonsson JI, (2010) The hematopoietic stem cell niche: low in oxygen but a nice place to be. J Cell Physiol 222: 17-22.
64. Kaufman DS, (2010) HIF hits Wnt in the stem cell niche. Nat Cell Biol 12: 926-927.
65. Du R, Lu KV, Petritsch C, Liu P, Ganss R, et al. (2008) HIF1alpha induces the recruitment of bone marrow-derived vascular modulatory cells to regulate tumor angiogenesis and invasion. Cancer Cell 13: 206-220.
66. Ceradini DJ, Gurtner GC, (2005) Homing to hypoxia: HIF-1 as a mediator of progenitor cell recruitment to injured tissue. Trends Cardiovasc Med 15: 57-63.
67. Rattigan Y, Hsu JM, Mishra PJ, Glod J, Banerjee D, (2010) Interleukin 6 mediated recruitment of mesenchymal stem cells to the hypoxic tumor milieu. Experimental Cell Research 316: 3417-3424.
68. Finger EC, Giaccia AJ, (2010) Hypoxia, inflammation, and the tumor microenvironment in metastatic disease. Cancer Metastasis Rev 29: 285-293.
69. Sakamoto T, Seiki M, (2010) A membrane protease regulates energy production in macrophages by activating hypoxia-inducible factor-1 via a non-proteolytic mechanism. J Biol Chem 285: 29951-29964.